

# Orgenesis

08:52 21 Jan 2020

## Orgenesis looks to raise \$9.24M in orchestrated private placement

Orgenesis Inc. (NASDAQ:ORGS), a developer of advanced cell therapies, is set to raise roughly \$9.24 million on a gross basis in another private placement to finance the expansion of its point-of-care cell-therapy platform.

Under the deal's terms, a private placement of 2.2 million shares of the company's stock has been arranged with select institutional investors, including The Phoenix Insurance Company and Sphera Global Healthcare Master Fund, at a strike price of \$4.20 per share.

Additional warrants to purchase up to 1 million shares of Orgenesis stock at an exercise price of \$5.50 have also been written.

**READ:** Orgenesis adds UC Davis to its point-of-care network for developing cell, gene therapy products

The offering is expected to close on or around January 23, provided closing conditions are met. In addition, the warrants can't be exercised until six months have passed and they expire three years from their issuance date.

Orgenesis's point-of-care platform is designed to develop and supply cell and gene products and therapies. With its introduction, hospitals are able to implement Orgenesis's proprietary automated, closed systems and know-how to collect, process and supply cells for various treatments such as the manufacturing of CAR-T cell therapies.

The Germantown, Maryland-based company provides centralized contract development and manufacturing organization (CDMO) services, as well as localized point-of-care development and processing centers through its subsidiary Orgenesis Maryland Inc.

**Price:** 7.68

**Market Cap:** \$168.93 m

### 1 Year Share Price Graph



### Share Information

**Code:** ORGS

**Listing:** NASDAQ

52 week	High	Low
	8.2	2.35

**Sector:** Pharma & Biotech

**Website:** [www.orgenesis.com](http://www.orgenesis.com)

### Company Synopsis:

*Orgenesis is a vertically-integrated biopharmaceutical company with unique expertise and experience in cell therapy development and manufacturing. The Company's MaSTherCell subsidiary is a global Contract Development and Manufacturing Organization (CDMO).*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).